Reply

Affiliations

¹ Department of Ophthalmology, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: domenico.lepore@unicatt.it.
² Department of Ophthalmology, Catholic University of the Sacred Heart, Rome, Italy.
³ Division of Pediatric Ophthalmology, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Comment

Domenico Lepore et al. Ophthalmology. 2018 Oct.

. 2018 Oct;125(10):e71-e72.

doi: 10.1016/j.ophtha.2018.04.012.

¹ Department of Ophthalmology, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: domenico.lepore@unicatt.it.
² Department of Ophthalmology, Catholic University of the Sacred Heart, Rome, Italy.
³ Division of Pediatric Ophthalmology, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

No abstract available

Comment on

Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E. Lepore D, et al. Ophthalmology. 2018 Feb;125(2):218-226. doi: 10.1016/j.ophtha.2017.08.005. Epub 2017 Sep 1. Ophthalmology. 2018. PMID: 28867130 Clinical Trial.
Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226).
Blair MP, Hilkert Rodriguez S, Chan RVP, Shapiro MJ. Blair MP, et al. Ophthalmology. 2018 Oct;125(10):e70-e71. doi: 10.1016/j.ophtha.2018.04.011. Ophthalmology. 2018. PMID: 30243341 No abstract available.